What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call.
AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
AngioDynamics (ANGO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.16 per share a year ago.
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sale.
AngioDynamics to Host Virtual Cardiovascular Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which wil.
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into th.
AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 35th Annual Healthcare MedTech and Service.
